Cannabis Science, Inc. (CBIS)

cannabis_print_logoCannabis Science, Inc. is a patient-oriented biotech company that specializes in cannabis formulation-based drug development and consulting. It is dedicated to meeting the needs of the community with products that are based on cannabinoid science. With the company’s unique understanding of metabolic processes, it aims to provide innovative treatment options for people whose medical needs were unmet.

As one of the longest standing companies in the cannabis industry, Cannabis Science continues to provide products that are medical cannabinoid formulations. The company is committed to providing those in need of new treatments for debilitating and life-threatening conditions with access to high-quality cannabinoid pharmaceuticals, and advocating their rights.

Cannabis Science works with drug development experts, as wells as clinical research and medical characteristic experts to develop, manufacture, and commercialize cannabinoid-based therapeutic approaches that can help treat many different types of critical ailments, including age-related medical conditions, neurobehavioral disorders, infections, and cancer. The company also works closely with regulatory agencies in their effort to alleviate suffering and to promote health of patients through cannabinoid science.

Cannabis Science, Inc. is a pioneering biotech company that creates medical cannabinoid formulations developed from cannabinoid compounds, which are derived from the cannabis plant. The material used by the company for clinical trials comes from GMP-compliant cultivation and production facilities. Its immediate focus is to develop treatment for different medical conditions, including certain types of cancer. The company continues to improve its standards to develop cutting edge treatments for cancer and other medical conditions.

Trading in the OTC under the symbol CBIS, Cannabis Science, Inc. is the first and only existing publicly traded biotech company on the market involved in formulations that are based on cannabinoid extracts. As the leader in the industry, the company consults and leads emerging businesses with a preferred business model that can mature into a key business model.


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements

IRVINE, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is entering a transition stage as trading of the Company’s shares is halted. Cannabis Science will continue to implement its corporate growth strategy and intends to resolve all outstanding regulatory reporting and filing requirements as it goes through its transition. “I can confirm that I found out yesterday that the trading of Cannabis Science’s shares has been halted by regulatory authorities - clearly the paperwork states ‘due to the financials not being filed as a fully-reporting issuer’.  While this is not a favorable situation, we are already addressing this matter directly with the authorities to protect the interests of our shareholders and stakeholders,” states Raymond C. Dabney, President, C.E.O. and Co-Founder of Cannabis Science.

Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions

IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP). The new Canadian-based partnership will expand Cannabis Science’s existing operations into Canada through its CDN EDP.

Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally

IRVINE, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is preparing to announce a number of exciting new partnerships and acquisitions as the Company prepares for a significant growth in revenue and positive cash flow from operations in key markets globally. The Company will be taking corporate actions to fast track this growth, including compiling the Company financials over the next quarter to achieve compliance with its fully reporting status requirements.

Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations

IRVINE, CA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has successfully completed reorganization of its European business to better align with the requirements of its customers, partners, and stakeholders. This move is expected to help improve the efficiency and effectiveness of CBIS’ European operations, and provide the necessary infrastructure to manage supply-chain logistics, new product development, and revenue growth. The Company’s activities, including cultivation, extraction, and manufacturing, will be headquartered in The Netherlands while all former Germany operations have been dissolved.

Cannabis Science, Inc. Successfully Completes Lab Testing for Its Proprietary, Short-Time Vacuum Distillation Process for Distribution of Purified High CBDA and CBD Water-Soluble Powders and Extracts Internationally

IRVINE, CA, July 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines and other products, is pleased to announce that its wholly-owned subsidiary, Cannabis Science Europe GmbH, has successfully completed testing and validation of its proprietary short-time vacuum distillation process for the purification and enhancement of cannabidiol (CBD) extract with high levels of Cannabidiolic Acid (CBDA) which subsequently is converted into purified water-soluble CBDA and CBD powder. The Company expects this new technology to drive sales growth with wholesale and retail customers internationally, subject to the jurisdictional regulatory constraints in targeted countries.